FCGR2A and neoplasm: Several pre- and clinical trials are testing GITR agonist antibodies, e.g., a FcγR-binding, mIgG2a anti-GITR antibody in mouse tumour models, or humanized GITR agonists in combination with immune checkpoint inhibitors (ICIs) in advanced human cancers.